NCT06733610View on ClinicalTrials.gov

CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

February 5, 2026

Study Completion Date

December 5, 2026

Conditions
Autoimmune Hemolytic AnemiaCD19/BCMA CAR T-cellsUniversal Allogeneic CAR T-cells
Interventions
BIOLOGICAL

universal allogeneic anti-CD19/BCMA CAR T-cells

A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells.

Trial Locations (1)

Unknown

RECRUITING

Regenerative Medicine Center and Red Blood Cell Disorders Center, Tianjin

All Listed Sponsors
collaborator

Xi'niao Biotech

UNKNOWN

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER